ConductScience.org, home

Paper357967

Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).

Dean J and 1 other. N Engl J Med, 1978. Cited by 211 papers, by iCite.

Cite this record

ConductScience Library. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts). Papers, record 357967. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/357967

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).
PubMed
Journal
N Engl J Med
PubMed
Year
1978
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
211
iCite
Relative citation ratio, by iCite
7.5
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dean JJ
2Schechter ANA N

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anemia, Sickle CellMajor topic
Hemoglobin, SickleMajor topic
Gels
Hemoglobin A
Hemoglobins
Humans
Kinetics
Models, Chemical
Molecular Conformation
Oxygen
Polymers
Temperature

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01932554Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain CrisisBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.

PMIDTitleJournalYearIn PapersSource
42903520Genetics of protein structures.Hlife2026https://conductscience.org/library/papers/42903520PubMed
41993330Decoupling Detection and Classification to Improve Morphological Phenotype Analysis of Sickle Red Blood Cells in Full-Scope Microscopy.bioRxiv2026https://conductscience.org/library/papers/41993330PubMed
39205400Sickle Cell Hemoglobin "Drugged" with Cyclic Peptides Is Aggregation Incompetent.J Phys Chem B2024https://conductscience.org/library/papers/39205400PubMed
33475200Bulk volume susceptibility difference between deoxyhemoglobin and oxyhemoglobin for HbA and HbS: A comparative study.Magn Reson Med2021https://conductscience.org/library/papers/33475200PubMed
31637552Diagnosing sickle cell disease and iron deficiency anemia in human blood by Raman spectroscopy.Lasers Med Sci2020https://conductscience.org/library/papers/31637552PubMed
31637541From fiction to science: clinical potentials and regulatory considerations of gene editing.Clin Transl Med2019https://conductscience.org/library/papers/31637541PubMed
28270342Cholelithiasis and its complications in sickle cell disease in a university hospital.Rev Bras Hematol Hemoter2017https://conductscience.org/library/papers/28270342PubMed
27437432Dynamic deformability of sickle red blood cells in microphysiological flow.Technology (Singap World Sci)2016https://conductscience.org/library/papers/27437432PubMed
26623213Musculoskeletal Manifestations of Sickle Cell Disease: A Review.Cureus2015https://conductscience.org/library/papers/26623213PubMed
25037561Protein carbamylation in kidney disease: pathogenesis and clinical implications.Am J Kidney Dis2014https://conductscience.org/library/papers/25037561PubMed
23599605Skeletal scintigraphy manifestations of hematologic disorders.Indian J Nucl Med2012https://conductscience.org/library/papers/23599605PubMed
10079113In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse.J Clin Invest1999https://conductscience.org/library/papers/10079113PubMed
8485022
The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
Br J Clin Pharmacol1993https://conductscience.org/library/papers/8485022PubMed
7640143Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.Br J Clin Pharmacol1995https://conductscience.org/library/papers/7640143PubMed
6940165Sickle cell hemoglobin fiber structure altered by alpha-chain mutation.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6940165PubMed
6933568Determination of deoxyhemoglobin S polymer in sickle erythrocytes upon deoxygenation.Proc Natl Acad Sci U S A1980https://conductscience.org/library/papers/6933568PubMed
6933482Sickle-cell hemoglobin: fall in osmotic pressure upon deoxygenation.Proc Natl Acad Sci U S A1980https://conductscience.org/library/papers/6933482PubMed
6752430Sickle cell trait: an update.J Natl Med Assoc1982https://conductscience.org/library/papers/6752430PubMed
6690472Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes.J Clin Invest1984https://conductscience.org/library/papers/6690472PubMed
6511979Sickle cell disease in Britain.J Clin Pathol1984https://conductscience.org/library/papers/6511979PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/357967

GET https://conductscience.org/api/papers/v1/357967/cited_by?page=2